LinkedIn Google+ Twitter Facebook

Molecular Intelligence Services

Our suite of tumor profiling services allows the physician to customize the level of profiling they deem necessary for each patient.


Our predefined profiles are helpful when navigating potential therapies within or outside guidelines, or when considering clinical trials.

MI Profile™
Multi-platform, solid tumor biomarker analysis for therapeutic decision support and clinical trials matching
Helpful when:

  • treating aggressive cancers, rare or refractory disease
  • looking for clinical trial opportunites

Next-Generation Sequencing Cancer Service
A standalone, solid tumor service to detect hundreds of hotspot mutations in the cancer genome. This can be performed on very small specimens (typically 8–10 unstained, unbaked and positively charged slides).

Individual Assays

The ordering physician can choose which assay(s) to order on an individual basis.

Single or Multiple Marker Analysis
Physician-directed single test or multiple marker analysis is available for any assay in the Caris Molecular Intelligence menu

Learn more about the multiple cancer profiling technologies we use or visit CarisMolecularIntelligence.com for more information.

Molecular Intelligence Service, from Caris Life Sciences®, provides evidence-based tumor information that associates biomarker status to agents with potential clinical benefit or potential lack of clinical benefit. Agents associated with clinical benefit are presented based on NCCN Compendium inclusion, relevance of tumor type, level of published evidence and strength of biomarker expression. Report information must be considered in conjunction with all other relevant information in respect of a given patient before determining the appropriate course of treatment. The selection of agents for re-treatment from prior chemotherapy regimens lies with the treating physician and must be done with careful consideration. Caris Molecular Intelligence Service was developed and its performance characteristics were determined by Caris Life Sciences, a medical laboratory CLIA-certified in compliance with the U.S. Clinical Laboratory Amendment Act of 1988 and all relevant U.S. state regulations. Caris Molecular Intelligence Service has not been approved by the United States Food and Drug Administration.



Explore cancer biomarkers, signaling pathways and cancer treatment research at CarisMolecularIntelligence.com.



Caris supports MyCancer.com, a new site for cancer patients about molecular profiling, cancer biomarkers and personalized treatment.

Find a Doctor

Find A Doctor

Find a local doctor who can help you determine if Caris Molecular Intelligence Service may be right for you.